ProMIS Neurosciences, is a TSX listed Company (PMN.TO) headquartered in Toronto, Ontario, with offices in Cambridge MA at the Cambridge Innovation Center. The Company’s mission is to discover and develop precision medicine therapeutics for best in class treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and ALS.
ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ & Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, ProMIS is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS. ProMIS has identified five target sites (epitopes) on toxic, misfolded strains of Amyloid beta, a root cause of AD, and created five antibodies specifically addressing these targets (without targeting amyloid beta monomer or plaque, known to be related to poor efficacy and side effects, respectively). ProMIS’ lead antibody product, PMN310, is in late preclinical development, with IND submission anticipated in late 2018.
Large pharma companies have invested over $1BB in clinical trials targeting Amyloid beta over the last decade. Significant scientific conclusions can be drawn from results of these trials, indicating that best in class AD antibody therapy should target specifically the toxic, misfolded strains of Amyloid beta and not the other forms. ProMIS’ AD program is specifically designed and is on track to achieve this goal.